Legato Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Legato Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$967K	Buy	+41,376	New	+$899K	0.09%	302

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Legato Capital Management's SNDX Position: Q1 2026 in Review

Legato Capital Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 41,376 shares worth $967K. The stake represents 0.09% of the portfolio and ranks #302 among its holdings.

246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Legato Capital Management held 41,376 shares of Syndax Pharmaceuticals worth $967K as of Q1 2026.
Syndax Pharmaceuticals was a new Legato Capital Management position in Q1 2026.
Syndax Pharmaceuticals made up 0.09% of Legato Capital Management's portfolio in Q1 2026, its #302 holding.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.